Logo image of MGNX

MACROGENICS INC (MGNX) Stock Fundamental Analysis

NASDAQ:MGNX - Nasdaq - US5560991094 - Common Stock - Currency: USD

2.76  -0.12 (-4.17%)

After market: 2.76 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MGNX. MGNX was compared to 571 industry peers in the Biotechnology industry. MGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MGNX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MGNX has reported negative net income.
MGNX had a negative operating cash flow in the past year.
In the past 5 years MGNX always reported negative net income.
MGNX had a negative operating cash flow in each of the past 5 years.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

MGNX's Return On Assets of -36.91% is in line compared to the rest of the industry. MGNX outperforms 59.50% of its industry peers.
MGNX has a Return On Equity of -81.30%. This is comparable to the rest of the industry: MGNX outperforms 51.69% of its industry peers.
Industry RankSector Rank
ROA -36.91%
ROE -81.3%
ROIC N/A
ROA(3y)-35.35%
ROA(5y)-37.77%
ROE(3y)-58.22%
ROE(5y)-56.86%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

With an excellent Gross Margin value of 95.07%, MGNX belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
MGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

6

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MGNX has more shares outstanding
MGNX has more shares outstanding than it did 5 years ago.
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

MGNX has an Altman-Z score of -5.45. This is a bad value and indicates that MGNX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.45, MGNX is doing worse than 64.12% of the companies in the same industry.
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.45
ROIC/WACCN/A
WACC9.44%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.75 indicates that MGNX has no problem at all paying its short term obligations.
MGNX's Current ratio of 3.75 is in line compared to the rest of the industry. MGNX outperforms 44.05% of its industry peers.
A Quick Ratio of 3.69 indicates that MGNX has no problem at all paying its short term obligations.
MGNX has a Quick ratio (3.69) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.69
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

MGNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.06%.
MGNX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.70%.
The Revenue has been decreasing by -0.45% on average over the past years.
EPS 1Y (TTM)-95.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.43%
Revenue 1Y (TTM)16.7%
Revenue growth 3Y-17.57%
Revenue growth 5Y-0.45%
Sales Q2Q%964.81%

3.2 Future

The Earnings Per Share is expected to grow by 2.58% on average over the next years.
Based on estimates for the next years, MGNX will show a small growth in Revenue. The Revenue will grow by 4.97% on average per year.
EPS Next Y23.36%
EPS Next 2Y-17.47%
EPS Next 3Y-1.27%
EPS Next 5Y2.58%
Revenue Next Year97.54%
Revenue Next 2Y-1.34%
Revenue Next 3Y6.17%
Revenue Next 5Y4.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGNX. In the last year negative earnings were reported.
Also next year MGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.47%
EPS Next 3Y-1.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MACROGENICS INC

NASDAQ:MGNX (2/21/2025, 8:00:01 PM)

After market: 2.76 0 (0%)

2.76

-0.12 (-4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners84.91%
Inst Owner Change-97.23%
Ins Owners0.68%
Ins Owner Change-1.72%
Market Cap173.22M
Analysts75.29
Price Target7.43 (169.2%)
Short Float %9.33%
Short Ratio9.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)134%
Min EPS beat(2)-48.21%
Max EPS beat(2)316.2%
EPS beat(4)1
Avg EPS beat(4)-34.63%
Min EPS beat(4)-378.4%
Max EPS beat(4)316.2%
EPS beat(8)3
Avg EPS beat(8)11.03%
EPS beat(12)4
Avg EPS beat(12)6.79%
EPS beat(16)5
Avg EPS beat(16)4.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.01%
Min Revenue beat(2)-50.61%
Max Revenue beat(2)42.6%
Revenue beat(4)1
Avg Revenue beat(4)-28.49%
Min Revenue beat(4)-67.02%
Max Revenue beat(4)42.6%
Revenue beat(8)2
Avg Revenue beat(8)-37.51%
Revenue beat(12)4
Avg Revenue beat(12)-23.44%
Revenue beat(16)6
Avg Revenue beat(16)-17.99%
PT rev (1m)0%
PT rev (3m)0.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.66%
EPS NY rev (1m)0%
EPS NY rev (3m)3.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)16.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)-2.44
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS2.25
BVpS1.91
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.91%
ROE -81.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.07%
FCFM N/A
ROA(3y)-35.35%
ROA(5y)-37.77%
ROE(3y)-58.22%
ROE(5y)-56.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.26%
Cap/Sales 2.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.69
Altman-Z -5.45
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)34.62%
Cap/Depr(5y)38.56%
Cap/Sales(3y)4.47%
Cap/Sales(5y)5.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.43%
EPS Next Y23.36%
EPS Next 2Y-17.47%
EPS Next 3Y-1.27%
EPS Next 5Y2.58%
Revenue 1Y (TTM)16.7%
Revenue growth 3Y-17.57%
Revenue growth 5Y-0.45%
Sales Q2Q%964.81%
Revenue Next Year97.54%
Revenue Next 2Y-1.34%
Revenue Next 3Y6.17%
Revenue Next 5Y4.97%
EBIT growth 1Y-0.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.88%
EBIT Next 3Y-7.82%
EBIT Next 5YN/A
FCF growth 1Y64.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66%
OCF growth 3YN/A
OCF growth 5YN/A